A new report highlights a number of worrying trends emerging in
regard to the increasing number of fake pharmaceuticals
infiltrating supply chains around the globe.
Swiss pharma Novartis today announced the largest manufacturing investment in its history, revealing plans for a $700m (€486.5m) biotech facility to be built alongside its new solid dose plant in the low cost, high quality biopharma hub of Singapore.
GlaxoSmithKline (GSK) is planning to strip itself down closer to
the bare bones of the business through further outsourcing and
offshoring, with hopes of making itself into a lean, mean, pharma
machine.
Sigma-Aldrich continued its strong year with both revenues and
pre-tax profits showing strong double-digit growth in the third
quarter predicting it will break the $2bn (€1.4bn) revenue mark
this year.
SAFC has announced its plans to build a new high potency
conjugation suite at its Missouri manufacturing plant in order to
target pharma clients developing novel anti-cancer drug conjugates.
Discovery Laboratories could see the end of its struggle to launch
its Surfaxin (lucinactant) drug on the US market as it has finally
resolved the manufacturing issues that have plagued the product for
months.
Pharmaceutical companies not only have to face the consequences of
a burgeoning counterfeit drug black market but have to contend with
the theft of their own manufactured drugs for illicit uses,
according to a US consumer advocacy...
Swiss supplier and services provider Lonza has added another
product to its catalogue of cell culture media, the most recent
addition to the offering of its new bioscience unit.
Chinese drug manufacturers could be given a 24-hour deadline by
regulators to pull unsafe pharmaceuticals off the market or face a
fine, a Chinese newspaper reported.
Novartis and Bayer Schering Pharma have finally settled their
disputes over multiple sclerosis (MS) drug Betaseron (interferon
beta-1b), with an agreement outlined in March now complete.
Britain's Eden Biodesign has been selected by Cancer Research UK as
the beneficiary of two new biomanufacturing contracts as its
biomanufacturing business continues to grow.
Acambis has had its smallpox vaccine approved by the US, coming one
step closer to closing another supply contract for the US Strategic
National Stockpile.
The end of the tunnel seems to be getting closer for South
African manufacturer Enaleni as the firm confirmed it will resume
production in its recently closed Durban facility in the next ten
days.
In the latest phase of growth at chemical firm SAFC's flagship high
potency active pharmaceutical ingredients (HPAPIs) facility in
Madison, Wisconsin, the site will be treated to another
multi-million dollar expansion and new...
Lonza's $200m (€147m) investment in China is continuing to shape up
as the firm announced its new small-scale exclusive synthesis
manufacturing plant will be up and running next month.
GlaxoSmithKline (GSK) and Merck Sharp & Dohme (MSD) have made
further moves in their plans to boost their presence in Singapore,
a region growing in popularity for biopharmaceutical research and
manufacture.
Solvay's first Chinese plant for a key chemical disinfectant is now
fully operational, serving the growing Chinese market and spreading
the international chemical group's global reach ever further.
China has announced an initial $1.7bn investment to bolster its
currently questionable ability to effectively monitor the quality
of the food and drugs manufactured within its borders.
Outsourcing Services Group (OSG) has announced it has sold its
contract manufacturing subsidiary OSG Norwich Pharmaceuticals to a
US private equity firm for an undisclosed amount.
Indian biotech heavyweight Biocon has today announced that its
joint venture with Abu Dhabi-based Neopharma has spawned new
company NeoBiocon, operating out of one of Dubai's newest
biotechnology parks.
Rentschler Biotechnologie has completed the first phase of a €50m
expansion of its biomanufacturing capacity with the launch of two
new bioreactors aimed at making protein-based drugs for biopharma
clients.
Biocatalysis expert Codexis has acquired BioCatalytics for an
undisclosed amount to strengthen its off-the-shelf biocatalyst
portfolio and give itself a larger 'window to the market'.
German speciality chemicals firm CABB has scooped up Swiss company
SF-Chem in a deal set to create a leading European supplier of
chlorine and speciality intermediates.
Danish firm Novozymes has been honoured by animal rights
organisation PETA for its efforts to provide animal-free
bioprocessing methods aimed at cutting animal testing during drug
development.
The US Food and Drug Administration (FDA) has released a draft
guideline document outlining a model for implementing the
International Conference on Harmonization's (ICH) Q10.
US biopharmaceutical company VGX has strengthened its position in
the plasmid DNA area with the award of two new patents covering the
use and manufacture of plasmid DNA.
As Outsourcing-Pharma.com continues to investigate the
circumstances of the Inyx group's insolvency problems, it can
be revealed that some of the senior management have been
involved at a senior level in other firms that have...
Indian pharmaceutical manufacturing company Shasun Chemicals and
Drugs has now got its eye fully on the US market after recent
approval of its new formulation facility in Puducherry.
Indian contract manufacturing organisation (CMO) Dishman
Pharmaceuticals has announced its plans to buy Solvay
Pharmaceuticals' fine chemicals and vitamin businesses for an
undisclosed sum.
AstraZeneca is planning to gradually withdraw from making its own
active pharmaceutical ingredients (APIs) and will use China as the
pinnacle of its new outsourcing plans.
Microtest Laboratories and Texcel Medical have teamed up to offer
biopharma firms services to help them overcome the hurdles of
developing "combination products" - a fast-growing market.
At a time when single-use manufacturing equipment is riding on a
surge of popularity, in-PharmaTechnologist.com talks to Vijay Singh
of GE Healthcare's newly acquired Wave Biotech unit about the
impact disposables will have on...
Dutch ingredients firm DSM has announced plans to carve out its
anti-infectives business and boost its presence in Asian markets
following a review of the active ingredient unit.
US firm Aptuit has announced it will invest $100m (€75m) in
India-based Laurus Labs to form a new joint venture - just a few
months after splurging a similar amount to expand its capabilities.
Lonza is building a new plant in its home country to become the
only contract manufacturer with large-scale capacity for making
highly potent active pharmaceutical ingredients (APIs).
After dismal second quarter results Patheon is stepping up its
resolve for 'damage control' and indicated that further cutbacks at
its problematic Puerto Rico plant are imminent.
The pharmaceutical and healthcare industries will help to push
trade between India and the United Kingdom up by 60 per cent within
three years, claims a soon-to-be released report.
The European Commission has released figures showing that there has
been a dramatic and concerning increase in pharmaceutical
counterfeiting, with seizures in Europe hitting an all time high of
over 2.5m items.
Indena offers custom development by leveraging the expertise of a specialized team devoted to designing and developing processes and analytical methods....
